Objective To explore the C-type fixation in the application of the catheter tunnel peritoneal dialysis. Methods One hundred and twenty patients undergoing peritoneal dialysis were selected from January to December 2014 in Xijin Hospital and were randomly divided into the control group and experiment group. The peritoneal dialysis catheters of the control group were fixed vertically at the tube orifice with surgical tape, while the peritoneal dialysis catheters of the experiment group were fixed horizontally first and then placed with a shape ofC and fixed at the tube orifice with surgical tape. The two groups were compared in terms of tunnel score, infection, tube shedding and pulling-induced stimuli. Result The tunnel score and the cases of infection rate, tube shedding and pulling-induced stimuli in the experiment group were lower and fewer than those of the control group with statistical significance (all P <0.05). Conclusion The type C fixation of tube for peritoneal dialysis can effectively reduce the incidence of infections in patients with peritoneal dialysis tunnel, reduce pulling-induced stimuli, and improve comfort of the patients.

In vitro fertilization and embryo transfer(IVF-ET) technology is one of the important means to treat infertility in recent years,although it had made remarkable progress in the field of reproductive medicine,but IVF-ET pregnancy success rate is not very ideal,the reasons that influent the success of IVF-ET include both parents donor of various unfavorable factors and stimulate ovulation itself produces all sorts of malpractices,its influence factors are complicated.In recent years,how to reduce the adverse factors affecting IVF-ET,to improve the success rate of pregnancy of IVF-ET has become the hot topics in the study of domestic clinical intervention in IVF-ET,and the domestic research shown that the quality of the follicle and endometrial environment is the key to determine the success of IVF-ET.

The paper investigates 31 foreign representative clinical knowledge base,analyzes development status including the establishment and maintenance institutions,user version control,localization application,clinical evidence resources,clinical specific content representation,evidence quality evaluation criteria and so on,summarizes revelation for domestic clinical knowledge base construction.

Sentinel lymph node biopsy has been proved to be the standard treatment for early breast cancer patients with negative axillary lymph node. The study related to the tracer has become one of the hottest topics in breast cancer research. At present, the biopsy is often performed using the tracer of isotope, blue dye or both of them. However, some deifciencies of the 2 tracers restrained their applications, which resulted that the rate of the procedure is limited to only about 60% of patients in developed countries and less than 5% of patients in China and other developing countries. In recent years, a variety of new tracers have emerged, such as indocyanine green, contrast-enhanced ultra-sound using microbubbles, superparamagnetic iron oxide nanoparticles. In this article, we introduced the characteristics of these 3 substances and reviewed the related research on the new tracers. In conclusion, the new tracers are still in the preliminary stage of research, and further research is needed for clinical application.

Gastric neuroendocrine neoplasms (G- NEN) is a type of relatively rare and heterogeneous tumors mainly derived from enterochromaffin-like cells (ECL-cells) localized in the gastric mucosa. The incidence of G-NEN has increased over the past few decades, which may contribute to factors such as improved clinical and pathological experience in diagnosing this disease, as well as increased access to endoscopy. The biological behavior, clinicalpathological features and treatment response of G-NEN are different from those of pancreatic or intestinal neuroendocrine neoplasms. The diagnosis of G-NEN mainly depends on endoscopy and pathology. Conventional imaging and somatostatin receptor imaging may help to diagnose the disease stage. Treatment requires a multidisciplinary approach that may include endoscopic resection, surgery, chemotherapy, somatostatin analogues, intervention, PRRT, etc. The present study reviews the relevant guidelines in combination of our experience and research and aims to elaborate the epidemiology, clinical classification, diagnostic modalities and treatment options.

Humans ; Hypertension ; Occupational Diseases ; Stress, Psychological

BACKGROUND:Although increasing studies have shown that autologous bone marrow stem celltransplantation can treat myocardial infarction, but there is a lack of large-scale multi-center randomized control ed trials to il ustrate the therapeutic effectiveness of autologous bone marrow stem celltreatment for myocardial infarction. OBJECTIVE:To systematical y evaluate the improvement of heart function in patients with myocardial infarction undergoing autologous bone marrow stem celltransplantation. METHODS:Cochrane Central Register of Control ed Trials (Central), MEDLINE, EMbase, PEDro (www.pedro.org.au), OpenSIGLE, National Technical Information Service (NTIS), CNKI, VIP database (VlP), Wanfang Data and Chinese biomedical literature database (CBM) were searched for the randomized control ed trials addressing bone marrow stem celltransplantation for heart function in patients with myocardial infarction. The bibliographies of the included studies were also searched. The time span was from database establishment to November 2012. The extracted data were analyzed by RevMan5.1. RESULTS AND CONCLUSION:A total of 14 randomized control ed trials were included. Results from the meta-analysis showed that the ejection fraction and cardiac output of patients undergoing bone marrow stem celltransplantation was significantly different from those of patients without celltransplantation (WMD=5.23, 95%CI (0.73, 9.72), P<0.01;WMD=1.69, 95%CI (1.23, 2.16), P<0.000 01). Current evidence has demonstrated that bone marrow stem celltransplantation can remarkably improve the ejection fraction and cardiac output of myocardial infarction patients, which can be clinical y recommended for improvement of heart function. Due to the limitations of the included studies, more large-sample, multi-center high-quality randomized control ed trials are required to further verify the therapeutic methods and effectiveness.

Objective The purpose of this study was to assess the antibacterial effects of hematoporphyrin monomethylether-photodynamic therapy (HMME-PDT) on Enterococcus faecalis within infected simulated lateral canals in vitro with different energy.Methods Simulated lateral canals were prepared on extracted teeth.The specimens were infected with Enterococcus faecalis and then were randomly divided into eight groups.Group A was considered as negative control,its specimens were irrigated with physiological saline.Group B was the positive control,they were irrigated with 5.25％ NaClO.Other groups were incubated with HMME at concentration of 40 μg/ml for 5 min,followed by exposure to light at 532 nm for 120 s with different powers in a spiral pattern.Groups were named C-H,in corresponding with the power 50,60,70,80,90,100 mW.Microbial samples (the dentin chips from simulated lateral canals) were taken before and after the treatments.The survival fractions in each simulated lateral canal was calculated by counting colony-forming units(CFUs).Results 1.The HMME-PDT-treated groups resulted in a significant reduction in the number of E.faecalis in simulated lateral canals compared with the negative controls(P＜0.05).2.The antibacterial effects of group D、E、F、G、H were higher than the NaCl0-irrigated group(P＜0.05).3.The difference of antibacterial effects between the F、G、H groups was in significant(P＞0.05).Conclusion HMME-PDT had significant inhibitive efficacy on Enterococcus faecalis within infected simulated lateral canals and the efficacy was power-depended.It can play the best effect with the power of 80 mW.

Objective To investigate the effects of early Xuebijing injection on procalcitonin (PCT) with septic shock patients.Methods Sixty-five patients with septic shock were randomly divided into the control group and Xuebijing injection group.The patients in Xuebijing injection group were received Xuebijing injection therapy(50 ml Xuebijing + 100 ml 0.9％ NaCl injection,2 times/d,for 7 d) besides basic treatment,while in the control group were received basic treatment including antibiotic susceptibility + early fluid resuscitation + correct acidosis.At the entering the ICU day and 1,3,5 d after treatment,patients were collected 5 ml venous blood serum C reactive protein(CRP) and PCT,and before treatment and at the 5th,7th day after treatment conducted APACHE Ⅱ evaluation to observation of curative effect of two groups.Results Before treatment,there were no significant difference in terms of heart rate,blood pressure,PCT,CRP,APACHE Ⅱ scores between the two groups (P ＞ 0.05).There was no significant difference in terms of PCT and CRP between the two groups at the 1 d after treatment(P ＞0.05).While at the 3th day after treatment,PCT and CRP of Xuebijing group were lower than of control group and the differences were significant ((7.37 ± 2.58) μg/L vs.(12.25 ± 3.32) μg/L,(64.32 ± 11.12) mg/L vs.(72.37 ± 12.42) mg/L;P ＜0.05).The APACHEⅡ score in control group at before and 5th,7th day after treatment were (20.48 ± 4.41),(16.52 ± 3.45),(12.78 ± 2.91) respectively,in Xuebijing injection group were (20.74 ± 4.73),(12.48 ± 2.76),(9.24 ± 6.67) respectively.And all indices were significant different time points between groups (P ＜ 0.05).At 7th day after treatment,15 cases were improved,10 cases progressed and 8 cases died in the control group and the effect rate was 75.8％ (25/33).Meanwhile,22 cases were improved,5 cases progressed and 5 cases died in the Xuebijing group and effect rate was 84.8％ (27/32).There was significant difference between two group(x2 =7.27,P =0.03).Conclusion Early Xuebijing injection application can inhibit the PCT r~tion of septic shock patients and improve the prognosis.

BACKGROUND:In recent years, the effectiveness of stem cel transplantation in the treatment of spinal cord injury has been validated in animal models, and mesenchymal stem cel transplantation for treatment of spinal cord injury has been studied most widely. Currently, there are a number of relevant clinical studies that have shown a good prospect. OBJECTIVE:To evaluate the efficacy and safety of mesenchymal stem cel transplantation for spinal cord injury in human with a system review. METHODS:PubMed database, EMBASE database, Cochrane Library, ISI Web of knowledge, CBM database, VIP database, CNKI database and Wanfang database were searched from their start year up to July 2015 for relevant randomized clinical trials on the treatment of spinal cord injury with mesenchymal stem cel transplantation. The key words were“spinal cord injury, paraplegia, cel transplantation, transplantation, mesenchymal stem cel , bone marrow transplantation, stem cel , randomized control ed trial”in English and Chinese, respectively. RESULTS AND CONCLUSION:A total of 260 articles were retrieved, including 6 randomized clinical trials (252 cases). In the aspects of ASIA touch sensation score, overal Frankel score and daily life activity training score, the patients undergoing mesenchymal stem cel transplantation were significantly superior to those in the control group (P<0.05). In addition, ASIA motor function score and residual urine volume were also improved in the patients undergoing mesenchymal stem cel transplantation, but there was no statistical difference (P>0.05). Compared with the control group, low fever was more common in the patients undergoing mesechymal stem cel transplantation (P<0.05). Another side effect was lower limb numbness, but there was no difference from the control group (P>0.05). These findings suggest that mesenchymal stem cel transplantation has limited efficacy in the treatment of spinal cord injury and cannot induce severe complications, but there is a need for high-quality randomized control ed trials to prove the efficiency and safety of mesenchymal stem cel transplantation for the treatment of spinal cord injury.